Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody

Table 4 Effects of adalimumab on anthropometry and bone health for paediatric Crohn’s disease activity index non-responder and responder

	PCDAI remission (n = 6)			PCDAI mild + moderate/severe (n = 12)
	Pre ADA	Post ADA	P value	Pre ADA	Post ADA	P value
Anthropometry1
Weight SDS	-0.2 [0.6-(-1.8)]	0.3 [1.7-(-1.5)]	NS	0.2 [1.7-(-4)]	-1.1 [0.5-(-3.5)]	NS
ΔWeight SDS	0.5 [1.8-(-0.7)]c	0.2 [0.9-(-0.4)]	NS	-0.9 [0.7-(-2.7)]c	-0.1 [1.7-(-1.7)]	NS
Height SDS	-0.2 [0-(-3.3)]	-0.1 [1.2-(-0.6)]	NS	-0.5 [0.8-(-2.3)]	-1.2 [0.8-(-4)]	NS
ΔHeight SDS	-0.1 [0-(-0.2)]	0.2 [1.4-(-0.5)]a	NS	-0.5 [0.9-(-2.5)]	-0.3 [0.3-(-2.7)]a	NS
BMI SDS	-0.4 [0.4-(-1.2)]	0.1 [2.7-(-0.8)]a	NS	-0.2 [2.5-(-2.6)]	-1 [0.1-(-3.6)]a	0.03
ΔBMI SDS	0.6 [2.5-(-0.7)]	0.3 [0.7-(-0.2)]a	NS	-0.2 [0.5-(-2)]	-1.1 [1.2-(-2.3)]a	NS
ΔPCDAI	-6 [45-(-20)]	-65 [-15-(-65)]a	0.02	20 [55-(-10)]	-14 [20-(-40)]a	0.001
Bone density
BMC	0.59 (0.5-0.9)	0.71 (0.6-0.9)	NS	0.66 (0.5-0.9)	0.65 (0.5-0.7)	NS
BMD SDS	-1.3 [0-(-2)]	-1.4 [0.3-(-2.7)]	NS	-1.8 [0.3-(-3.3)]	-2.3 [-1.3-(-3.8)]	0.02
BMAD SDS	-1.2 [-0.5-(-2.7)]	-1.2 [-0.6-(-2)]	NS	-1.5 [0.1-(-2.8)]	-1 [0.2-(-2.8)]	NS
Calcium homeostasis
PTH	22 (19-29)c	33 (23-77)	NS	34 (22-49)c	43 (22-72)	NS
25-OHD	54 (34-73)	44 (13-82)	NS	61 (10-107)	44 (22-60)	NS
1.25-OHD	81 (37-116)	55 (22-81)	NS	51 (22-180)	26 (5-73)	NS
Bone markers
BAP	31 (20-57)	38 (28-44)a	NS	46 (14-90)	21 (17-35)a	NS
Osteocalcin	55 (41-101)	84 (34-90)	NS	60 (16-125)	37 (17-87)	NS
C-telopeptide	0.7 (0.3-1.2)	1 (0.2-1.1)	NS	1 (0.5-1.9)	1.1 (0.5-1.1)	NS
Corticosteroids
Daily dose	5 (2.5-45)	5 (5-15)	NS	7.5 (2.5-10)	40 (10-50)	NS
Cumulative dose	262 (0-927)	638 (0-2800)	NS	1960 (0-3640)	1330 (0-2188)	NS

¹Results are presented as median (range).

^cP < 0.05 vs mild + moderate/severe pre-adalimumab;

^aP < 0.05 vs mild + moderate/severe post-adalimumab. BMC: Bone mineral content; BMD: Bone mineral density; SDS: Standard deviation score; BMAD: Bone mineral apparent density; PTH: Parathyroid hormone; 25-OHD: 25-hydroxycholecalciferol; 1,25-OHD: 1,25-dihydroxycholecalciferol; BAP: Bone alkaline phosphatase; ADA: Adalimumab.